These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38932369)

  • 21. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model.
    Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH
    J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.
    Fortunato F; Campanozzi A; Maffei G; Arena F; Carri VD; Rollo T; Lopalco PL; Martinelli D
    Ital J Pediatr; 2024 Mar; 50(1):45. PubMed ID: 38454523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season.
    Consolati A; Farinelli M; Serravalle P; Rollandin C; Apprato L; Esposito S; Bongiorno S
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study.
    Alharbi A; Yousef A; Zubani A; Alzahrani M; Al-Hindi M; Alharbi S; Alahmadi T; Alabdulkarim H; Kazmierska P; Beuvelet M
    Adv Ther; 2024 Apr; 41(4):1419-1435. PubMed ID: 38356106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WITHDRAWN: Immunoglobulin for preventing respiratory syncytial virus infection.
    Wang EE; Tang NK
    Cochrane Database Syst Rev; 2007 Jul; 2006(3):CD001725. PubMed ID: 17636681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin for preventing respiratory syncytial virus infection.
    Wang EE; Tang NK
    Cochrane Database Syst Rev; 2000; (2):CD001725. PubMed ID: 10796658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
    Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.
    Zornoza Moreno M; Pérez Martín JJ; Moreno MCG; Abellán MPR
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357439. PubMed ID: 38857859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of respiratory syncytial virus vaccination during pregnancy to prevent lower respiratory tract illness in newborns and infants: a systematic review and meta-analysis of randomized controlled trials.
    Ma J; Chen L; Tang S; Shi Y
    Front Pediatr; 2023; 11():1260740. PubMed ID: 38357264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.
    ; Le TG; Ngo L; Mehta S; Do VD; Thach TQ; Vu XD; Nguyen DT; Cohen A
    Res Rep Health Eff Inst; 2012 Jun; (169):5-72; discussion 73-83. PubMed ID: 22849236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.
    Wegzyn C; Toh LK; Notario G; Biguenet S; Unnebrink K; Park C; Makari D; Norton M
    Infect Dis Ther; 2014 Dec; 3(2):133-58. PubMed ID: 25297809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
    Sanders SL; Agwan S; Hassan M; van Driel ML; Del Mar CB
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD009417. PubMed ID: 31446622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
    Dagan R; Hammitt LL; Seoane Nuñez B; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Chang Y; Currie A; Grenham A; Shroff M; Takas T; Mankad VS; Leach A; Villafana T
    J Pediatric Infect Dis Soc; 2024 Feb; 13(2):144-147. PubMed ID: 38219024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.
    Mankad VS; Leach A; Chang Y; Wählby Hamrén U; Kiazand A; Kubiak RJ; Takas T; Villafana T; Shroff M
    Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.